Capricor Therapeutics (CAPR) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$24.6 million.
- Capricor Therapeutics' Income towards Parent Company fell 9567.63% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$57.5 million, marking a year-over-year decrease of 6825.08%. This contributed to the annual value of -$40.4 million for FY2024, which is 8059.67% down from last year.
- Capricor Therapeutics' Income towards Parent Company amounted to -$24.6 million in Q3 2025, which was down 9567.63% from -$25.9 million recorded in Q2 2025.
- Over the past 5 years, Capricor Therapeutics' Income towards Parent Company peaked at -$829093.0 during Q4 2023, and registered a low of -$25.9 million during Q2 2025.
- For the 5-year period, Capricor Therapeutics' Income towards Parent Company averaged around -$9.3 million, with its median value being -$7.2 million (2023).
- Per our database at Business Quant, Capricor Therapeutics' Income towards Parent Company skyrocketed by 8921.39% in 2023 and then crashed by 74565.53% in 2024.
- Capricor Therapeutics' Income towards Parent Company (Quarter) stood at -$6.4 million in 2021, then dropped by 20.79% to -$7.7 million in 2022, then surged by 89.21% to -$829093.0 in 2023, then crashed by 745.66% to -$7.0 million in 2024, then crashed by 250.44% to -$24.6 million in 2025.
- Its last three reported values are -$24.6 million in Q3 2025, -$25.9 million for Q2 2025, and -$7.0 million during Q4 2024.